Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 10,343 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all
Not listed No phase listed Observational

Natural History Study of Factor IX Treatment and Complications

NCT02502409
View directory record Official record
Conditions
Factor IX Deficiency
Interventions
Standard care with blood and urine sample collection
Other
Lead sponsor
Skane University Hospital
Other
Eligibility
Not listed
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 29, 2026, 1:50 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Ultrasound for Socket Healing Evaluation

NCT06017193
View directory record Official record
Conditions
Healing Wound, Alveolar; Wound, Alveolar Bone Loss, Image, Dent Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

NCT01580293
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 29, 2026, 1:50 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of P-188 NF in DMD Patients

NCT03558958
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
P-188 NF
Drug
Lead sponsor
Phrixus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 25 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 29, 2026, 1:50 AM EDT
Active, not recruiting Phase 2 Interventional

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

NCT04732416
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
HM15136
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
2 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

NCT01720316
View directory record Official record
Conditions
Schizo-affective Disorder, Bipolar Disorder
Interventions
Glycine, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 29, 2026, 1:50 AM EDT
Terminated Phase 2 Interventional Results available

Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease

NCT00863434
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia
Interventions
clofarabine, cytarabine, filgrastim
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants

NCT00167544
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Encephalomalacia, Premature Birth
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Week to 3 Weeks
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 29, 2026, 1:50 AM EDT
Terminated Not applicable Interventional Results available

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

NCT02498444
View directory record Official record
Conditions
Single Ventricle
Interventions
Treprostinil
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 29, 2026, 1:50 AM EDT
Completed No phase listed Observational

Osteogenesis Imperfecta (OI) Quality of Life Survey Pilot Project 2

NCT02793063
View directory record Official record
Conditions
Osteogenesis Imperfecta, Brittle Bone Disorders
Interventions
Web-based Survey
Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 29, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional

HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis

NCT06175104
View directory record Official record
Conditions
Heart Defects, Congenital, Anxiety in Pregnancy, Depression, Postpartum, Trauma, Psychological, Neurodevelopmental Disorders
Interventions
HeartGPS
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

Allopurinol Combination Study

NCT01001338
View directory record Official record
Conditions
Gout
Interventions
RDEA594, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 29, 2026, 1:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Doxycycline in Cutaneous Schwannoma (NF2)

NCT05521048
View directory record Official record
Conditions
Neurofibromatosis Type 2
Interventions
Doxycycline Injection [Doxy]
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
8 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Not applicable Interventional

Cosmetic Outcomes of Umbilical Hernia Incisions

NCT06738121
View directory record Official record
Conditions
Umbilical Hernia
Interventions
Infra-umbilical incision, Transumbilical incision
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

NCT02498652
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 2.5 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Anaheim, California • DeLand, Florida • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

NCT00030264
View directory record Official record
Conditions
Neurofibromatosis Type 1, Precancerous Condition
Interventions
Methotrexate, Vinblastine
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 25 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

NCT02947087
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Prolastin-C, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 29, 2026, 1:50 AM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 29, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional

MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease

NCT06853158
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Music therapy, Health education
Behavioral · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
14 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

Growth Hormone Use in Adults With Prader-Willi Syndrome

NCT00444964
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Nutropin AQ
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
16 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 29, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability

NCT01411163
View directory record Official record
Conditions
Huntington's Disease
Interventions
Creatine monohydrate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
26 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 29, 2026, 1:50 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Biomarkers Related to Bone in Pediatric Gaucher Disease

NCT06116071
View directory record Official record
Conditions
Gaucher Disease, Bone Diseases
Interventions
Not listed
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Other
Eligibility
5 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 29, 2026, 1:50 AM EDT
Terminated Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Hip Or Knee

NCT00985621
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, oxycodone, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 29, 2026, 1:50 AM EDT